
LINK . SPRINGER . COM {
}
Title:
Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer | Breast Cancer Research and Treatment
Description:
Background. Partial cross-resistance to paclitaxel and docetaxel has been demonstrated in pre-clinical studies. Patients and methods. We retrospectively evaluated the efficacy of weekly paclitaxel 80 mg/m2 in 82 patients with docetaxel-resisitant metastatic breast cancer. Docetaxel resistance was classified into primary resistance, defined as progressive disease while receiving docetaxel, and secondary resistance, defined as progression after achievement of a documented clinical response to docetaxel. Secondary resistance was subclassified according to the interval between the final infusion of docetaxel and the start of weekly paclitaxel into: (1) short interval, ≦120 days, and (2) long interval, >120 days. Results. The response rate of the 82 patients was 19.5% (95% confidence interval, 10.8–27.9%). The response rate according to the docetaxel resistance category was: primary resistance (n=24), 8.3%; secondary resistance (n=58), 24.1% (short interval [n=39], 17.9%, and long interval, [n=19], 36.8%). The differences in response rates among the three categories were statistically significant (p=0.0247, Cochran–Mantel–Haenszel test). The interval between from the final docetaxel infusion and disease progression were predictors for response of weekly paclitaxel. Conclusion. Weekly paclitaxel is modestly effective and safe in docetaxel-resistant metastatic breast cancer patients. However, weekly paclitaxel should not be recommended for primary resistance patients with docetaxel.
Website Age:
28 years and 1 months (reg. 1997-05-29).
Matching Content Categories {📚}
- Health & Fitness
- Education
- Science
Content Management System {📝}
What CMS is link.springer.com built with?
Custom-built
No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of link.springer.com audience?
🌠 Phenomenal Traffic: 5M - 10M visitors per month
Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Link.springer.com Make Money? {💸}
We can't tell how the site generates income.
Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.
Keywords {🔍}
cancer, breast, docetaxel, google, scholar, pubmed, cas, paclitaxel, patients, metastatic, resistance, article, oncol, weekly, clin, efficacy, phase, treatment, interval, research, study, taxol, privacy, cookies, content, yasuhiro, response, access, publish, search, katsumata, uno, advanced, horwitz, res, author, data, information, log, journal, docetaxelresistant, yonemori, hajime, ando, fujiwara, primary, secondary, safety, discover, chemotherapy,
Topics {✒️}
anthracenedione-resistant breast cancer month download article/chapter world health organization metastatic breast cancer cochran–mantel–haenszel test fant sb horwitz ringel sb horwitz hajime uno dose-dense therapy asmar gn hortobagyi real-world study gika ma dimopoulos advanced anthracycline-resistant docetaxel resistance category privacy choices/manage cookies partial cross-resistance multidrug resistance protein breast cancer full article pdf related subjects author correspondence docetaxel successfully treated dual her2 blockade medical oncology division phase ii study primary resistance patients dose-escalation study randomized phase ii pre-clinical studies weekly paclitaxel int single-agent docetaxel check access evidence-based review exogenous guanosine 5′-triphospahate sutherland jl misset kane wa bierman buchholz ef smit kalofonos la moulopoulos seeber ym rustum instant access anthracycline resistance paclitaxel-induced remission paclitaxel-pretreated previously discontinued patients conditions privacy policy docetaxel resistance european economic area line chemotherapy yasuhiro fujiwara final docetaxel infusion
Schema {🗺️}
WebPage:
mainEntity:
headline:Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer
description:
Background. Partial cross-resistance to paclitaxel and docetaxel has been demonstrated in pre-clinical studies.
Patients and methods. We retrospectively evaluated the efficacy of weekly paclitaxel 80 mg/m2 in 82 patients with docetaxel-resisitant metastatic breast cancer. Docetaxel resistance was classified into primary resistance, defined as progressive disease while receiving docetaxel, and secondary resistance, defined as progression after achievement of a documented clinical response to docetaxel. Secondary resistance was subclassified according to the interval between the final infusion of docetaxel and the start of weekly paclitaxel into: (1) short interval, ≦120 days, and (2) long interval, >120 days.
Results. The response rate of the 82 patients was 19.5% (95% confidence interval, 10.8–27.9%). The response rate according to the docetaxel resistance category was: primary resistance (n=24), 8.3%; secondary resistance (n=58), 24.1% (short interval [n=39], 17.9%, and long interval, [n=19], 36.8%). The differences in response rates among the three categories were statistically significant (p=0.0247, Cochran–Mantel–Haenszel test). The interval between from the final docetaxel infusion and disease progression were predictors for response of weekly paclitaxel.
Conclusion. Weekly paclitaxel is modestly effective and safe in docetaxel-resistant metastatic breast cancer patients. However, weekly paclitaxel should not be recommended for primary resistance patients with docetaxel.
datePublished:
dateModified:
pageStart:237
pageEnd:241
sameAs:https://doi.org/10.1007/s10549-004-2184-0
keywords:
docetaxel
metastatic breast cancer
paclitaxel
predictive factor
resistance
taxane
Oncology
image:
isPartOf:
name:Breast Cancer Research and Treatment
issn:
1573-7217
0167-6806
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Kluwer Academic Publishers
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Kan Yonemori
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Noriyuki Katsumata
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Hajime Uno
affiliation:
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Koji Matsumoto
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Tsutomu Kouno
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Shinya Tokunaga
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Yasuhiro Yamanaka
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Chikako Shimizu
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Masashi Ando
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Masahiro Takeuchi
affiliation:
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Yasuhiro Fujiwara
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer
description:
Background. Partial cross-resistance to paclitaxel and docetaxel has been demonstrated in pre-clinical studies.
Patients and methods. We retrospectively evaluated the efficacy of weekly paclitaxel 80 mg/m2 in 82 patients with docetaxel-resisitant metastatic breast cancer. Docetaxel resistance was classified into primary resistance, defined as progressive disease while receiving docetaxel, and secondary resistance, defined as progression after achievement of a documented clinical response to docetaxel. Secondary resistance was subclassified according to the interval between the final infusion of docetaxel and the start of weekly paclitaxel into: (1) short interval, ≦120 days, and (2) long interval, >120 days.
Results. The response rate of the 82 patients was 19.5% (95% confidence interval, 10.8–27.9%). The response rate according to the docetaxel resistance category was: primary resistance (n=24), 8.3%; secondary resistance (n=58), 24.1% (short interval [n=39], 17.9%, and long interval, [n=19], 36.8%). The differences in response rates among the three categories were statistically significant (p=0.0247, Cochran–Mantel–Haenszel test). The interval between from the final docetaxel infusion and disease progression were predictors for response of weekly paclitaxel.
Conclusion. Weekly paclitaxel is modestly effective and safe in docetaxel-resistant metastatic breast cancer patients. However, weekly paclitaxel should not be recommended for primary resistance patients with docetaxel.
datePublished:
dateModified:
pageStart:237
pageEnd:241
sameAs:https://doi.org/10.1007/s10549-004-2184-0
keywords:
docetaxel
metastatic breast cancer
paclitaxel
predictive factor
resistance
taxane
Oncology
image:
isPartOf:
name:Breast Cancer Research and Treatment
issn:
1573-7217
0167-6806
volumeNumber:89
type:
Periodical
PublicationVolume
publisher:
name:Kluwer Academic Publishers
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Kan Yonemori
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Noriyuki Katsumata
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Hajime Uno
affiliation:
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Koji Matsumoto
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Tsutomu Kouno
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Shinya Tokunaga
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Yasuhiro Yamanaka
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Chikako Shimizu
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Masashi Ando
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Masahiro Takeuchi
affiliation:
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
type:Organization
type:Person
name:Yasuhiro Fujiwara
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:
hasPart:
isAccessibleForFree:
cssSelector:.main-content
type:WebPageElement
["Periodical","PublicationVolume"]:
name:Breast Cancer Research and Treatment
issn:
1573-7217
0167-6806
volumeNumber:89
Organization:
name:Kluwer Academic Publishers
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Kan Yonemori
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Noriyuki Katsumata
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Hajime Uno
affiliation:
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
type:Organization
name:Koji Matsumoto
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Tsutomu Kouno
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Shinya Tokunaga
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Yasuhiro Yamanaka
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Chikako Shimizu
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Masashi Ando
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
name:Masahiro Takeuchi
affiliation:
name:Kitasato University Graduate School
address:
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
type:PostalAddress
type:Organization
name:Yasuhiro Fujiwara
affiliation:
name:National Cancer Center Hospital
address:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
name:Division of Biostatistics, Kitasato University Graduate School, Minato-ku, Tokyo, Japan
name:Breast and Medical Oncology Division, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan
WebPageElement:
isAccessibleForFree:
cssSelector:.main-content
External Links {🔗}(94)
- Income figures for https://www.springernature.com/gp/authors
- Monthly income for https://link.springernature.com/home/
- Learn how profitable https://order.springer.com/public/cart is on a monthly basis
- How much profit does https://submission.springernature.com/new-submission/10549/3 generate?
- Profit of https://www.springernature.com/gp/librarians/licensing/agc/journals
- Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10402251
- http://scholar.google.com/scholar_lookup?&title=The%20efficacy%20of%20chemotherapy%20with%20docetaxel%20and%20paclitaxel%20in%20anthracycline-reistant%20breast%20cancer&journal=Int%20J%20Oncol&volume=15&pages=381-386&publication_year=1999&author=Pivot%2CX&author=Asmar%2CL&author=Hortobagyi%2CGN income
- How much profit is https://doi.org/10.3816%2FCBC.2000.n.002 making per month?
- What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11899388?
- How much does http://scholar.google.com/scholar_lookup?&title=Taxanes%20for%20breast%20cancer%3A%20an%20evidence-based%20review%20of%20randomized%20phase%20II%20and%20phase%20III%20trials&journal=Clin%20Breast%20Cancer&doi=10.3816%2FCBC.2000.n.002&volume=1&pages=32-40&publication_year=2000&author=Sparano%2CJA pull in?
- What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=423966?
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Promotion%20of%20microtubule%20assembly%20in%20vitro%20by%20taxol&journal=Nature&volume=277&pages=665-667&publication_year=1979&author=Schiff%2CPB&author=Fant%2CJ&author=Horwitz%2CSB
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=6103535 making per month?
- What's the profit of http://scholar.google.com/scholar_lookup?&title=Taxol%20stabilizes%20microtubules%20in%20mouse%20fibroblast%20cells&journal=Proc%20Natl%20Acad%20Sci%20USA&volume=77&pages=1561-1565&publication_year=1980&author=Schiff%2CPB&author=Horwitz%2CSB?
- What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=6113842?
- What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Taxol%20assembles%20tubuin%20in%20the%20absence%20of%20exogenous%20guanosine%205%E2%80%B2-triphospahate%20or%20micro%20tubule-associated%20proteins&journal=Biochemistry&volume=20&pages=3247-3252&publication_year=1981&author=Schiff%2CPB&author=Horwitz%2CSB?
- What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8105478?
- How much does http://scholar.google.com/scholar_lookup?&title=Mechanism%20of%20mitotic%20block%20and%20inhibition%20of%20cell%20proliferation%20by%20taxol%20at%20low%20concentration&journal=Proc%20Natl%20Acad%20Sci%20USA&volume=90&pages=9552-9556&publication_year=1993&author=Jordan%2CMA&author=Toso%2CRJ&author=Wilson%2CL net monthly?
- Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1671606
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Studies%20with%20RPR%2056976%20%28Taxotere%29%3A%20a%20semisynthetic%20analogue%20of%20Taxol&journal=J%20Natl%20Cancer%20Inst&volume=83&pages=288-291&publication_year=1991&author=Ringel%2CI&author=Horwitz%2CSB produce monthly?
- Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9000560's earnings
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Bcl-2%20is%20the%20guardian%20of%20microtuble%20integrity&journal=Cancer%20Res&volume=57&pages=229-233&publication_year=1997&author=Haldar%2CS&author=Basu%2CA&author=Croce%2CC
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Cellular%20uptake%20and%20efflux%20of%20docetaxel%20and%20paclitaxel%20in%20P388%20cell%20line&journal=Proc%20Am%20Assoc%20Cancer%20Res&volume=35&publication_year=1994&author=Riou%2CJF&author=Petitgenet%2CO&author=Combeau%2CC&author=Lavelle%2CF
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7918121's total income per month
- What's http://scholar.google.com/scholar_lookup?&title=Paclitaxel%20%28taxol%29%20and%20docetaxel%20%28taxotere%29%3A%20not%20simply%20two%20of%20a%20kind&journal=Ann%20Oncol&volume=5&pages=495-505&publication_year=1994&author=Verweij%2CJ&author=Clavel%2CM&author=Chevallier%2CB's gross income?
- What's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10653871?
- Profit of http://scholar.google.com/scholar_lookup?&title=Factors%20predicting%20for%20efficacy%20and%20safety%20of%20docetaxel%20in%20a%20compassionate%20use%20cohort%20of%20825%20heavily%20pretreated%20advanced%20breast%20cancer%20patients&journal=J%20Clin%20Oncol&volume=18&pages=562-573&publication_year=2000&author=Alexandre%2CJ&author=Bleuzen%2CP&author=Bonneterre%2CJ&author=Sutherland%2CW&author=Misset%2CJL&author=Guastalla%2CJ&author=Viens%2CP&author=Faivre%2CS&author=Chahine%2CA&author=Spielman%2CM&author=Bensmaine%2CA&author=Marty%2CM&author=Mahjoubi%2CM&author=Cvitkovic%2CE
- Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11208824
- Income figures for http://scholar.google.com/scholar_lookup?&title=Efficacy%20of%20docetaxel%2060%20mg%2Fm2in%20patients%20with%20metastatic%20breast%20cancer%20according%20to%20the%20status%20of%20anthracycline%20resistance&journal=J%20Clin%20Oncol&volume=19&pages=336-342&publication_year=2001&author=Ando%2CM&author=Watanabe%2CT&author=Nagata%2CK&author=Narabayashi%2CM&author=Adachi%2CI&author=Katsumata%2CN
- How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8546908?
- How much does http://scholar.google.com/scholar_lookup?&title=A%20late%20phase%20II%20study%20of%20RP56976%20%28docetaxel%29%20in%20patients%20with%20advanced%20or%20recurrent%20breast%20cancer&journal=Br%20J%20Cancer&volume=73&pages=210-216&publication_year=1996&author=Adachi%2CI&author=Watanabe%2CT&author=Takashima%2CS&author=Narabayashi%2CM&author=Horikoshi%2CN&author=Aoyama%2CH&author=Taguchi%2CT bring in each month?
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8523050?
- How much does http://scholar.google.com/scholar_lookup?&title=Phase%20II%20of%20docetaxel%20in%20advanced%20anthracycline-resistant%20or%20anthracenedione-resistant%20breast%20cancer&journal=J%20Clin%20Oncol&volume=13&pages=2879-2885&publication_year=1995&author=Ravdin%2CPM&author=Burris%2CHAIII&author=Cook%2CG&author=Eisenberg%2CP&author=Kane%2CM&author=Bierman%2CWA&author=Mortimer%2CJ&author=Genevois%2CE&author=Bellet%2CRE bring in each month?
- How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9779712 pull in monthly?
- How much does http://scholar.google.com/scholar_lookup?&title=Dose-dense%20therapy%20with%20weekly%201-hour%20paclitaxel%20infusions%20in%20the%20treatment%20of%20metastatic%20breast%20cancer&journal=J%20Clin%20Oncol&volume=16&pages=3353-3361&publication_year=1998&author=Seidman%2CAD&author=Hudis%2CCA&author=Albanel%2CJ&author=Tong%2CW&author=Tepler%2CI&author=Currie%2CV&author=Moynahan%2CME&author=Theodoulou%2CM&author=Gollub%2CM&author=Baselga%2CJ&author=Norton%2CL pull in monthly?
- Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11709565
- Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Multicenter%20phase%20II%20trial%20of%20weekly%20paclitaxel%20in%20woman%20with%20metastatic%20breast%20cancer&journal=J%20Clin%20Oncol&volume=19&pages=4216-4223&publication_year=2001&author=Perez%2CEA&author=Vogel%2CCL&author=Irwin%2CDH&author=Kirshner%2CJJ&author=Patel%2CR
- How much profit is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11081452 making per month?
- How much does http://scholar.google.com/scholar_lookup?&title=Single-agent%20docetaxel%20in%20metastatic%20breast%20cancer%20patients%20pre-treated%20with%20anthracycline%20and%20paclitaxel%3A%20partial%20cross-resistance%20between%20paclitaxel%20and%20docetaxel&journal=Anti-Cancer%20Drugs&volume=11&pages=617-621&publication_year=2000&author=Lin%2CYC&author=Chang%2CHK&author=Wang%2CCH&author=Chen%2CJS&author=Liaw%2CCC make?
- What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9779713 each month?
- Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=A%20phase%20II%20study%20of%20docetaxel%20in%20patients%20with%20paclitaxel-resitant%20metastatic%20breast%20cancer&journal=J%20Clin%20Oncol&volume=16&pages=3362-3368&publication_year=1998&author=Valero%2CV&author=Jones%2CSE&author=Hoff%2CDD&author=Boosner%2CDJ&author=Mennel%2CRG&author=Ravadin%2CPM&author=Holmes%2CFA&author=Rahman%2CZ&author=Schottstaedt%2CMW&author=Erban%2CJK&author=Esparaza-Guerra%2CL&author=Earnhart%2CRH&author=Hortobagyi%2CGN&author=BurrisIII%2CHA
- What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11036960?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=paclitaxel-induced%20remission%20in%20docetaxel%20refractory%20anthracycline-pretreated%20metastatic%20breast%20cancer&journal=Anti-Cancer%20Drugs&volume=11&pages=569-571&publication_year=2000&author=Suzuma%2CT&author=Sakurai%2CT&author=Yoshimura%2CG&author=Umemura%2CT&author=Tamaki%2CT&author=Naito%2CY?
- Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11706529
- What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Metastatic%20breast%20cancer%20with%20resistance%20to%20both%20anthracycline%20and%20docetaxel%20successfully%20treated%20with%20weekly%20paclitaxel&journal=Int%20J%20Clin%20Oncol&volume=6&pages=55-58&publication_year=2001&author=Ishitobi%2CM&author=Shin%2CE&author=Kikkawa%2CN?
- Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12538462
- Explore the financials of http://scholar.google.com/scholar_lookup?&title=European%20organization%20for%20research%20and%20treatment%20of%20cancer%20%28EORTC%29%2008957%20phase%20II%20study%20of%20topotecan%20in%20combination%20with%20cisplatin%20as%20second-line%20treatment%20of%20refractory%20and%20sensitive%20small%20cell%20lung%20cancer&journal=Clin%20Cancer%20Res&volume=9&pages=143-150&publication_year=2003&author=Ardizzoni%2CA&author=Manegolod%2CC&author=Debruyne%2CC&author=Gaafar%2CR&author=Buchholz%2CE&author=Smit%2CEF&author=Lianes%2CP&author=ten%20Velde%2CG&author=Bosquee%2CL&author=Legrand%2CC&author=Neumaier%2CC&author=King%2CK
- Earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14751151
- How much revenue does http://scholar.google.com/scholar_lookup?&title=Second-line%20chemotherapy%20with%20gemcitabine%20and%20cisplatin%20in%20paclitaxel-pretreated%2C%20platinum-sensitive%20ovarian%20cancer%20patients.%20A%20Hellenic%20Cooperative%20Oncology%20Group%20Study&journal=Gynecol%20Oncol&volume=92&pages=152-159&publication_year=2004&author=Papadimitriou%2CCA&author=Fountzilas%2CG&author=Aravantios%2CG&author=Kalofonos%2CC&author=Moulopoulos%2CLA&author=Briassoulis%2CE&author=Gika%2CD&author=Dimopoulos%2CMA produce monthly?
- What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14610615?
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Activity%20of%20docetaxel%20in%20paclitaxel-resistant%20ovarian%20cancer%20cells&journal=Cancer%20Chemother%20Pharmacol&volume=53&pages=247-252&publication_year=2004&author=Sato%2CS&author=Kigawa%2CJ&author=Kanamori%2CY&author=Itamachi%2CH&author=Oishi%2CT&author=Shimada%2CM&author=Iba%2CT&author=Naniwa%2CJ&author=Uegaki%2CK&author=Terakawa%2CN?
- How much income is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9496387 earning monthly?
- Revenue of http://scholar.google.com/scholar_lookup?&title=Comparative%20antitumor%20efficacy%20of%20docetaxel%20and%20paclitaxel%20in%20nude%20mice%20bearing%20human%20tumor%20xenografts%20that%20overexpress%20the%20multidrug%20resistance%20protein%20%28MRP%29&journal=Ann%20Oncol&volume=8&pages=1221-1228&publication_year=1997&author=Vanhoefer%2CU&author=Cao%2CS&author=Harstrick%2CA&author=Seeber%2CS&author=Rustum%2CYM
- Profit of https://citation-needed.springer.com/v2/references/10.1007/s10549-004-2184-0?format=refman&flavour=references
- Learn how profitable https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Kan%20Yonemori is on a monthly basis
- What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Kan%20Yonemori%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Noriyuki%20Katsumata's financial summary
- See how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Noriyuki%20Katsumata%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en makes per month
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Hajime%20Uno generate?
- How much profit does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Hajime%20Uno%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate?
- How much profit is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Koji%20Matsumoto making per month?
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Koji%20Matsumoto%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in monthly?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tsutomu%20Kouno?
- Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tsutomu%20Kouno%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shinya%20Tokunaga have monthly?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shinya%20Tokunaga%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
- https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yasuhiro%20Yamanaka's total income per month
- How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yasuhiro%20Yamanaka%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en generate monthly?
- How much income is https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Chikako%20Shimizu earning monthly?
- How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Chikako%20Shimizu%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
- How much income does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masashi%20Ando have?
- What are the total earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masashi%20Ando%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Masahiro%20Takeuchi pull in?
- What's the profit of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Masahiro%20Takeuchi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What's the total monthly financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yasuhiro%20Fujiwara?
- How much revenue does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yasuhiro%20Fujiwara%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en bring in?
- How much profit is https://s100.copyright.com/AppDispatchServlet?title=Efficacy%20of%20weekly%20paclitaxel%20in%20patients%20with%20docetaxel-resistant%20metastatic%20breast%20cancer&author=Kan%20Yonemori%20et%20al&contentID=10.1007%2Fs10549-004-2184-0©right=Springer&publication=0167-6806&publicationDate=2005-02&publisherName=SpringerNature&orderBeanReset=true making per month?
- Income figures for https://citation-needed.springer.com/v2/references/10.1007/s10549-004-2184-0?format=refman&flavour=citation
- What's the financial gain of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
- Find out how much https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research earns monthly
- How much does https://www.springernature.com/gp/products bring in each month?
- What's the financial outcome of https://www.springernature.com/gp/librarians?
- Discover the revenue of https://www.springernature.com/gp/societies
- https://www.springernature.com/gp/partners's financial summary
- Financial intake of https://www.springer.com/
- What's https://www.nature.com/'s gross income?
- How much does https://www.biomedcentral.com/ earn?
- What's the total monthly financial gain of https://www.palgrave.com/?
- How much revenue does https://www.apress.com/ bring in?
- How much money does https://www.springernature.com/gp/legal/ccpa make?
- See how much https://www.springernature.com/gp/info/accessibility makes per month
- What's the income of https://support.springernature.com/en/support/home?
- Learn how profitable https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations is on a monthly basis
- Financial intake of https://www.springernature.com/
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Clipboard.js
- Prism.js
CDN Services {📦}
- Crossref